Genetix Pharmaceuticals Inc.

Geert-Jan Mulder is a general partner at Forbion Capital Partners, having joined the ABN AMRO Capital Life Sciences (AAC LS) team in 2001 as one of the investment managers. He led multiple deals in both Europe and US. Prior to joining Forbion, he was Clinical Research Manager for The Netherlands for Byk Gulden (now Nycomed), where his department dealt with the design and execution of numerous phase I/IIa, IIb, IIIa and IIIb clinical trials in the fields of Gastroenterology, Respiratory Medicine (asthma and COPD), Intensive Care Medicine and Imaging. He was a Member of the Global Medical Marketing group of the Respiratory Franchise and was involved in the line extension program for Pantozol (pantoprazole). Prior to joining Byk Gulden he was with Searle (now Pfizer) working in the field of Arthritis & Pain as a Medical Adviser, being involved in the clinical development as well as local and European advocate development in the pre-launch roll-out for Celebrex (celecoxib). In addition to his position as general partner at Forbion, Geert-Jan provides scientific feedback to a number of portfolio companies and actively works together with management teams in various task forces or advisory committees to add value to their clinical, regulatory programs and corporate strategy. His efforts supported robust development programs, IND filings, a Special Protocol Approval (SPA) by the FDA and Orphan designation for 3 potential treatments in the US as well as EU. Geert-Jan took the lead in the Series B financing round of PanGenetics B.V. and serves on the board. After co-leading the Series B round of Transave Inc. Geert-Jan serves on the board and actively supports the Company in their overall and clinical strategy. In 2007 Geert-Jan became chairman of the board of Genetix Pharmaceuticals Inc. Before going public he represented AAC LS on the board of Acorda Therapeutics where he was part of the Fampridine-SR board panel to evaluate a new clinical endpoint in Multiple Sclerosis, which became the basis for their successful pivotal phase III trial. Geert-Jan received his Medical Degree from the University of Utrecht in the Netherlands. During and after his internships he spent two years as a clinician in Obstetrics and Gynaecology at the University Medical Center of Utrecht (UMC). In 2001, Geert-Jan was awarded his Registration as Pharmaceutical Physician.